National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$33.75
add to cart

Rights & Permissions

topleft topright

Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary (2011)
Board on Health Care Services (HCS)
Board on Health Sciences Policy (HSP)
Food and Nutrition Board (FNB)

Citation Manager

. "Acronyms." Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press, 2011.

Please select a format:

BibTeX EndNote RefMan


Page
103
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary

Acronyms

ACCORD Action to Control Cardiovascular Risk in Diabetes

ACE inhibitor angiotensin-converting enzyme inhibitor

ADA American Dietetic Association

APOE apolipoprotein E

CAST Cardiac Arrhythmia Suppression Trial

CBER Center for Biologics Evaluation and Research

CD4 cells CD4+ T-lymphocytes

CDC Centers for Disease Control and Prevention

CDER Center for Drug Evaluation and Research

CDRH Center for Devices and Radiological Health

CEA carcinoembryonic antigen

CFSAN Center for Food Safety and Applied Nutrition

CHD coronary heart disease

CLIA Clinical Laboratory Improvement Amendments

CMS Centers for Medicare & Medicaid Services

COAG Clarification of Optimal Coagulation through Genetics

COPD chronic obstructive pulmonary disease

CRN Council for Responsible Nutrition

CRP C-reactive protein

CSPI Center for Science in the Public Interest

CVD cardiovascular disease

Page
103

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 103
Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary Acronyms ACCORD Action to Control Cardiovascular Risk in Diabetes ACE inhibitor angiotensin-converting enzyme inhibitor ADA American Dietetic Association APOE apolipoprotein E CAST Cardiac Arrhythmia Suppression Trial CBER Center for Biologics Evaluation and Research CD4 cells CD4+ T-lymphocytes CDC Centers for Disease Control and Prevention CDER Center for Drug Evaluation and Research CDRH Center for Devices and Radiological Health CEA carcinoembryonic antigen CFSAN Center for Food Safety and Applied Nutrition CHD coronary heart disease CLIA Clinical Laboratory Improvement Amendments CMS Centers for Medicare & Medicaid Services COAG Clarification of Optimal Coagulation through Genetics COPD chronic obstructive pulmonary disease CRN Council for Responsible Nutrition CRP C-reactive protein CSPI Center for Science in the Public Interest CVD cardiovascular disease

OCR for page 104
Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary DDT drug development tools DHA docosahexaenoic acid EMEA European Medicines Agency ESA erythropoiesis-stimulating agent FAA Federal Aviation Administration FDA Food and Drug Administration FDAAA Food and Drug Administration Amendments Act GAO Government Accountability Office GI gastrointestinal GMA Grocery Manufacturers Association HDL high-density lipoprotein HDL-C high-density lipoprotein cholesterol HER2 human epidermal growth factor receptor 2 HHS Department of Health and Human Services HIV human immunodeficiency virus HRT hormone replacement therapy IOM Institute of Medicine IVD in vitro diagnostic LDL low-density lipoprotein LDL-C low-density lipoprotein cholesterol MI myocardial infarction MRI magnetic resonance imaging NCI National Cancer Institute NHANES National Health and Nutrition Examination Survey NHLBI National Heart, Lung, and Blood Institute NIH National Institutes of Health NLEA Nutrition, Labeling, and Education Act ODS Office of Dietary Supplements PCI percutaneous coronary intervention PET positron emission tomography PML progressive multifocal leukoencephalopathy PRO patient-reported outcomes PSA prostate-specific antigen

OCR for page 105
Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary PSTC Predictive Safety Testing Consortium RT-PCR reverse-transcriptase polymerase chain reaction SABRe Systems Approach to Biomarker Research in Cardiovascular Disease SPECT single photon emission computed tomography TLR target lesion revascularization TSH thyroid-stimulating hormone USDA United States Department of Agriculture VRE vancomycin-resistant enterococci

OCR for page 106
Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary This page intentionally left blank.